Acceleron Pharma Statistics
Share Statistics
Acceleron Pharma has 0
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -43.77 and the forward
PE ratio is null.
Acceleron Pharma's PEG ratio is
-1.93.
| PE Ratio | -43.77 |
| Forward PE | n/a |
| PS Ratio | 78.54 |
| Forward PS | n/a |
| PB Ratio | 8.5 |
| P/FCF Ratio | -54.02 |
| PEG Ratio | -1.93 |
Financial Ratio HistoryEnterprise Valuation
Acceleron Pharma has an Enterprise Value (EV) of 6.62B.
| EV / Sales | 71.55 |
| EV / EBITDA | -40.82 |
| EV / EBIT | -50.8 |
| EV / FCF | -49.21 |
Financial Position
The company has a current ratio of 14.85,
with a Debt / Equity ratio of 0.01.
| Current Ratio | 14.85 |
| Quick Ratio | 14.85 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.15 |
| Debt / FCF | -0.18 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -19.42% and Return on Invested Capital is -19.41%.
| Return on Equity | -19.42% |
| Return on Assets | -17.81% |
| Return on Invested Capital | -19.41% |
| Revenue Per Employee | $296,548.08 |
| Profits Per Employee | $-532,147.44 |
| Employee Count | 312 |
| Asset Turnover | 0.1 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 21K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is 0.13, so Acceleron Pharma's
price volatility has been higher than the market average.
| Beta | 0.13 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,265,302 |
Income Statement
In the last 12 months, Acceleron Pharma had revenue of 92.52M
and earned -166.03M
in profits. Earnings per share was -2.92.
| Revenue | 92.52M |
| Gross Profit | 92.52M |
| Operating Income | -167.31M |
| Net Income | -166.03M |
| EBITDA | -162.16M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.92 |
Full Income StatementBalance Sheet
The company has 670.95M in cash and 24.08M in
debt, giving a net cash position of 646.88M.
| Cash & Cash Equivalents | 670.95M |
| Total Debt | 24.08M |
| Net Cash | 646.88M |
| Retained Earnings | -877.44M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -130.33M
and capital expenditures -4.2M, giving a free cash flow of -134.53M.
| Operating Cash Flow | -130.33M |
| Capital Expenditures | -4.2M |
| Free Cash Flow | -134.53M |
| FCF Per Share | -2.37 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -180.83% and -179.45%.
| Gross Margin | 100% |
| Operating Margin | -180.83% |
| Pretax Margin | -179.42% |
| Profit Margin | -179.45% |
| EBITDA Margin | -175.27% |
| EBIT Margin | -180.83% |
| FCF Margin | -145.4% |
